Bank of The Ozarks boosted its position in shares of Abbott Laboratories (NYSE:ABT) by 65.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 27,637 shares of the healthcare product maker’s stock after purchasing an additional 10,970 shares during the quarter. Bank of The Ozarks’ holdings in Abbott Laboratories were worth $1,577,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of ABT. Farmers National Bank raised its holdings in shares of Abbott Laboratories by 2.4% in the second quarter. Farmers National Bank now owns 3,653 shares of the healthcare product maker’s stock worth $178,000 after acquiring an additional 85 shares during the last quarter. Flagship Harbor Advisors LLC raised its holdings in shares of Abbott Laboratories by 0.7% in the second quarter. Flagship Harbor Advisors LLC now owns 12,341 shares of the healthcare product maker’s stock worth $600,000 after acquiring an additional 87 shares during the last quarter. Hedeker Wealth LLC raised its holdings in shares of Abbott Laboratories by 0.5% in the second quarter. Hedeker Wealth LLC now owns 24,678 shares of the healthcare product maker’s stock worth $1,199,000 after acquiring an additional 116 shares during the last quarter. L & S Advisors Inc increased its stake in Abbott Laboratories by 0.7% in the second quarter. L & S Advisors Inc now owns 21,348 shares of the healthcare product maker’s stock valued at $1,038,000 after purchasing an additional 150 shares during the last quarter. Finally, Moors & Cabot Inc. increased its stake in Abbott Laboratories by 0.3% in the second quarter. Moors & Cabot Inc. now owns 48,781 shares of the healthcare product maker’s stock valued at $2,376,000 after purchasing an additional 161 shares during the last quarter. Institutional investors own 72.46% of the company’s stock.
In other Abbott Laboratories news, insider Daniel Gesua Sive Salvadori sold 28,319 shares of the company’s stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $54.92, for a total transaction of $1,555,279.48. Following the sale, the insider now owns 102,117 shares in the company, valued at $5,608,265.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Jared Watkin sold 996 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $58.87, for a total value of $58,634.52. Following the sale, the senior vice president now owns 69,511 shares in the company, valued at approximately $4,092,112.57. The disclosure for this sale can be found here. Insiders have sold 144,318 shares of company stock worth $8,596,826 in the last 90 days. 0.76% of the stock is currently owned by insiders.
Shares of Abbott Laboratories (ABT) opened at $63.62 on Tuesday. Abbott Laboratories has a one year low of $42.31 and a one year high of $64.60. The stock has a market capitalization of $111,100.00, a P/E ratio of 61.17, a price-to-earnings-growth ratio of 1.91 and a beta of 1.52. The company has a current ratio of 2.26, a quick ratio of 1.86 and a debt-to-equity ratio of 0.87.
Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Abbott Laboratories had a return on equity of 13.88% and a net margin of 1.74%. The firm had revenue of $7.59 billion for the quarter, compared to analysts’ expectations of $7.38 billion. During the same quarter in the prior year, the firm posted $0.65 earnings per share. Abbott Laboratories’s revenue for the quarter was up 42.3% compared to the same quarter last year. equities research analysts expect that Abbott Laboratories will post 2.86 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 15th. Shareholders of record on Friday, April 13th will be paid a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 1.76%. The ex-dividend date of this dividend is Thursday, April 12th. Abbott Laboratories’s payout ratio is currently 107.69%.
TRADEMARK VIOLATION NOTICE: This article was posted by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/03/13/abbott-laboratories-abt-shares-bought-by-bank-of-the-ozarks.html.
Abbott Laboratories Profile
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.